InMed Pharmaceuticals reports oral Alzheimer's treatment INM-901 demonstrates therapeutic brain levels.
InMed Pharmaceuticals Inc. announced that its oral formulation INM-901 has successfully demonstrated therapeutic levels in the brain for Alzheimer's disease treatment. The small molecule drug candidate, following successful preclinical research, could potentially lower treatment costs and address challenges associated with existing large molecule therapies. InMed is continuing with further research, including chemistry, manufacturing, and controls, to support an IND submission.
August 20, 2024
6 Articles